about
Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge aheadAssessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: focus on the cancer hallmark of tumor angiogenesisTargeting tissue factor on tumor vascular endothelial cells and tumor cells for immunotherapy in mouse models of prostatic cancer.Immunotherapy for choroidal neovascularization in a laser-induced mouse model simulating exudative (wet) macular degeneration.Targeting tissue factor for immunotherapy of choroidal neovascularization by intravitreal delivery of factor VII-Fc chimeric antibody.Factor VII-verteporfin for targeted photodynamic therapy in a rat model of choroidal neovascularization.Targeting tissue factor on tumour cells and angiogenic vascular endothelial cells by factor VII-targeted verteporfin photodynamic therapy for breast cancer in vitro and in vivo in mice.The immunoconjugate "icon" targets aberrantly expressed endothelial tissue factor causing regression of endometriosisNatural killer cells are crucial for the efficacy of Icon (factor VII/human IgG1 Fc) immunotherapy in human tongue cancerRetroviral-mediated transmission of a mouse VL30 RNA to human melanoma cells promotes metastasis in an immunodeficient mouse model.hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor for immunotherapy of uterine serous papillary carcinoma.Effective treatment of chemoresistant breast cancer in vitro and in vivo by a factor VII-targeted photodynamic therapy.Intratumoral injection of adenoviral vectors encoding tumor-targeted immunoconjugates for cancer immunotherapy.Tumor cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-dependent and-independent mechanisms.Targeting tumor vasculature endothelial cells and tumor cells for immunotherapy of human melanoma in a mouse xenograft model.Selective and effective killing of angiogenic vascular endothelial cells and cancer cells by targeting tissue factor using a factor VII-targeted photodynamic therapy for breast cancer.Tissue factor is an angiogenic-specific receptor for factor VII-targeted immunotherapy and photodynamic therapy.Targeting tissue factor as a novel therapeutic oncotarget for eradication of cancer stem cells isolated from tumor cell lines, tumor xenografts and patients of breast, lung and ovarian cancer.IL-21 Enhances Natural Killer Cell Response to Cetuximab-Coated Pancreatic Tumor Cells.Tissue factor-targeted immunotherapy of melanoma and triple negative breast cancer using a second generation ICON.The future of immune checkpoint blockade immunotherapy: towards personalized therapy or towards combination therapy.Icon immunoconjugate treatment results in regression of red lesions in a non-human primate (Papio anubis) model of endometriosis.Therapeutic Antibody-Like Immunoconjugates against Tissue Factor with the Potential to Treat Angiogenesis-Dependent as Well as Macrophage-Associated Human DiseasesFluorescent nanodiamonds and their use in biomedical researchPhotodynamic Therapy as an Emerging Treatment Modality for Cancer and Non-Cancer DiseasesDual-Targeting of Tumor Cells and Tumor Neovasculature by Tissue Factor- Targeted Photodynamic TherapyFactor VII-Targeted Photodynamic Therapy for Breast Cancer and Its Therapeutic Potential for Other Solid Cancers and LeukemiaMapping of angiogenic markers for targeting of vectors to tumor vascular endothelial cellsAntigen-Driven Stimulation of B-Lymphocytes In VitroTissue factor as a new target for CAR-NK cell immunotherapy of triple-negative breast cancer
P50
Q28397132-13C07B41-7656-4028-819A-C7D4C991C7D9Q28397726-BD95E42F-6A07-4CD7-A9FE-4B5E7E0279EBQ30453862-D4CC4B1A-560B-4682-B9A5-42F959C60016Q31131792-682E0E34-6AA9-4804-94E9-4CDBAD8A04DBQ33279027-667859BB-F65F-4988-8CC6-C9D1BF1FA3B6Q33428484-C006A74B-4086-478B-97B1-647DC69DDEDEQ33588136-B5634664-5401-4B32-BEAE-7DA4F1918CAAQ33597282-9033F807-D12D-4733-AD54-3D7E43E7A5B6Q33715830-24683863-C118-496B-9C38-7BD72F521B07Q34028774-25E51646-E33D-4494-8AD9-D3D8CCFA1D55Q34253625-014D1D0A-C617-45AE-8B22-8875FD615712Q35006931-E89AAD46-D991-47E2-8B9E-73B029541BDFQ35201112-5177A059-957E-4964-8713-E2A8BB459A0EQ35850648-A88C4CE2-75D7-452F-AEFE-F7AFE21E147BQ36417960-D111EA35-4C77-482B-9068-A0185392B2FEQ37633792-AA01C0D7-DF4D-4EFF-A350-7C6258349DE8Q37639757-34036C9B-29B7-4FF3-B703-D1AE91488885Q37702117-93E3F848-F030-4CB1-8176-B2BAA4DDD7D6Q40642974-E530296B-8110-47AE-B7BD-782C6ED5EBE3Q45907494-00A950D6-55AD-4C3F-855B-5170D407D5B3Q47127400-D206B3D8-1F12-42AF-A6CA-2F957B7C0F09Q50107907-99B72BBC-2027-4697-98B8-555CBB46BB94Q60584701-014C8868-6C80-4E53-8633-B1B060B6E734Q60584702-CF47D384-ED62-4324-A0FF-FC072C8E9858Q60584703-B16F0E15-DFC5-4CB6-8A5F-FCD04802BA60Q60584705-A24A93E0-1465-4EC9-BE13-95362FA6524AQ60584707-51198218-8D11-4562-9200-95B67852F88AQ60584708-1815476C-674B-4E2E-8363-2C3D538961C6Q60584709-699B77CA-E26B-4147-9CE4-B477AC3C2CD4Q89767304-1E312858-B7E3-420A-B96F-D619D992E569
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Zhiwei Hu
@ast
Zhiwei Hu
@en
Zhiwei Hu
@es
Zhiwei Hu
@nl
Zhiwei Hu
@sl
type
label
Zhiwei Hu
@ast
Zhiwei Hu
@en
Zhiwei Hu
@es
Zhiwei Hu
@nl
Zhiwei Hu
@sl
prefLabel
Zhiwei Hu
@ast
Zhiwei Hu
@en
Zhiwei Hu
@es
Zhiwei Hu
@nl
Zhiwei Hu
@sl
P106
P1153
7404211573
P21
P31
P496
0000-0002-0023-1170